Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
IPO Year:
Exchange: NASDAQ
Website: https://www.alphatau.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/15/2023 | $8.00 | Buy | Citigroup |
4/24/2023 | $9.00 | Buy | H.C. Wainwright |
4/14/2022 | $20.00 | Overweight | Cantor Fitzgerald |
4/8/2022 | $19.00 | Overweight | Piper Sandler |
4/4/2022 | $21.00 | Buy | Citigroup |
JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Company's Board of Directors in order to assume the full-time position of Alpha Tau's Chief Commercial Officer. Mr. Melnyk served most recently as CEO of Fortovia Therapeutics, an oncology supportive care pharmaceutical and medical device company headquartered in Raleigh, North Carolina. Before that, he served as Chief Commercial Officer of Novocure, and led the construction of the global commercial platform and infrastructure
JERUSALEM, June 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS) (NASDAQ:DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Mr. Gary Leibler has resigned from the Company's board of directors and its audit committee, for reasons unrelated to the Company. "I wish to thank Gary for his years of dedicated service to the Company, as a member of the board of directors since the early days of Alpha Tau," commented Alpha Tau CEO Uzi Sofer. "He has added tremendous value ever since his first day with us, and we have benefitted greatly from his expertise and experience." Gary Leibler, who also serves as
JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
No Severe Long-Term Toxicities With 2-Year Local Recurrence-Free Survival At 77%
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 8.33 percent increase over losses of $(0.12) per share from the same period last year.
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone - Effect seen across both Panc02 and KPC tumor models -JERUSALEM, May 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the presentation of new preclinical data at the 2024 congress of the European Society for Radiotherapy and Oncology (ESTRO), currently taking place in Glasgow, UK, examining observed responses in distant untreated tumors, otherwise known as an abscopal e
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
Piper Sandler analyst Jason Bednar reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and lowers the price target from $8 to $7.
Gainers Reshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 6.7% to $0.26 during Wednesday's after-market session. The company's market cap stands at $4.8 million. Semler Scientific (NASDAQ:SMLR) shares rose 5.99% to $52.87. The market value of their outstanding shares is at $363.3 million. China Pharma Holding (AMEX:CPHI) stock rose 5.82% to $0.1. The company's market cap stands at $3.2 million. CARISMA Therapeutics (NASDAQ:CARM) stock rose 5.07% to $2.9. The market value of their outstanding shares is at $117.0 million. Purple Biotech (NASDAQ:PPBT) stock increased by 4.99% to $0.7. The company's market cap stands at $17.2 million. Sangamo Therapeutics (NASDAQ:SGMO) shares incre
Citigroup initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $8.00
H.C. Wainwright initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $9.00
Cantor Fitzgerald initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $20.00
Piper Sandler initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $19.00
Citigroup initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $21.00
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
NEW YORK, NY / ACCESSWIRE / September 17, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day September Small-Cap Conference taking place Wednesday and Thursday, September 18-19, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.Presentation Schedule*All Times EDTWednesday, September 18, 2024 (Day 1)8:30-9:00MtronPTI (MPTI)The Gorman-Rupp Company (GRC)Lilium (LILM)*****9:15-9:45The LGL Group, Inc. (LGL)Natural Gas Services Group (NGS)Harvard Bioscience (HBIO)Lifetime Brands, Inc. (LCUT)10:00-10:30Daktronics (DAKT)Arcosa, Inc (
JERUSALEM, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present a corporate overview and update at the H.C. Wainwright 26th Annual Global Investment Conference on September 10th, 2024 and in the Sidoti Virtual Investor Conference on September 18-19th, 2024 and will participate in the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference on September 26th, 2024 and the Lytham Partners Fall 2024 Investor Conference on October 1st, 2024. Event:H.C. Wainwright 26th Annual Global Investment ConferenceD
- First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to-treat superficial cancers, with an overall response rate of almost 100% in treated lesions, no moderate or severe long-term toxicities noted, and a 2-year local recurrence-free survival was estimated at 77% - - Cash, cash equivalents & deposits balance of $74.1 million with runway of at least two years - JERUSALEM, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported seco
The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat indications including skin, head & neck, and oral cavity. Initial response data demonstrated an overall response rate of almost 100% in treated lesions and a complete response rate of 89%. With follow-up as long as 51 months (median follow-up of 14-months), no moderate or severe long-term toxicities were noted, and 2-year local recurrence-free survival was estimated at 77%. JERUSALEM, June 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced t
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Global Healthcare Conference on June 5th, 2024. Event:Jefferies Global Healthcare ConferenceDate:June 5th, 2024Time:1:30-1:55 PM ESTLocation:New York, NY Mr. Levy will also be available for 1x1 investor meetings at the conference. Please reach out to your Jefferies representative to schedule. About Alpha Tau Medical Ltd. Founded in 2016, Alpha Tau is an Israeli medical device company that f
- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow - - First patient with liver metastases treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada - - Patient recruitment for ReSTART U.S. multi-center pivotal trial and for pancreatic cancer feasibility and safety studies in Canada and Israel currently ongoing - - Cash, cash equivalents, deposits & restricted deposits balance of $80.7 million with runway of at least two years - JERUSALEM, May 20, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau",
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with liver cancer metastases has been treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada. The trial seeks to recruit up to 10 patients who are eligible for a two-staged hepatectomy to resect liver metastases of colorectal cancer. Specifically, in the first stage, as many metastatic tumors as possible will be surgically removed in a non-curative intervention, while Alpha DaRT sources will be i
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone - Effect seen across both Panc02 and KPC tumor models - JERUSALEM, May 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the presentation of new preclinical data at the 2024 congress of the European Society for Radiotherapy and Oncology (ESTRO), currently taking place in Glasgow, UK, examining observed responses in distant untreated tumors, otherwise known as an abscopa
JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present at the following investor conferences in May 2024. Event:Guggenheim Securities Radiopharmaceuticals DayFormat:PresentationDate:May 13, 2024Time:11:30AM ETLocation:New York, NY Event:H.C. Wainwright 2ndAnnual BioConnect Investor ConferenceFormat:Fireside ChatDate:May 20, 2024Time:2PM ETLocation:New York, NY Mr. Levy will also be available for 1x1 investor meetings at the conferences. Please reach out to your Guggenheim Securities and H.C. Wainwri
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Radiopharma Innovation Summit on April 11th, 2024. Event:Jefferies Radiopharma Innovation SummitDate:April 11, 2024Time:12:40-1:10 PM ESTLocation:New York, NY Mr. Levy will also be available for 1x1 investor meetings at the conference. Please reach out to your Jefferies representative to schedule. About Alpha Tau Medical Ltd. Founded in 2016, Alpha Tau is an Israeli medical device company